WASHINGTON (dpa-AFX) - Novo Nordisk (NVO) said Friday that the Committee for
Medicinal Products for Human Use or CHMP, under the European Medicines Agency or
EMA, has issued a positive opinion, recommending an update of the label for
BRUSSELS (dpa-AFX) - Novo Nordisk A/S (NVO) said that its shareholders
approved the Company's statutory Annual Report 2016, The actual remuneration of
the Board of Directors for 2016 and the remuneration level for 2017; the final
Insulin prices have been rising — increases that mean some people are spending as much on monthly diabetes-related expenses as their mortgage payment.
As a result, the companies that make insulin have been under fire from the public and...
U.S. private equity firm Lone Star is closer to taking control of Portugal's Novo Banco with an offer to inject up to 1 billion euros ($1.07 billion) into the bank in return for a 75 percent stake, sources told Reuters.
BM&FBOVESPA presents here the final proposals of the Regulations for the BM&FBOVESPA special corporate governance segments (Novo Mercado and Level 2) which will be put before a Closed Hearing. In the first phase, which begins today and...
The pharmaceutical industry, rich with innovative players and shaken by impending regulatory changes, is a well-worn topic on Wall Street. Adam Feuerstein joined Benzinga’s Pre-Market Prep radio show to comment on the status of the market and...
The following are the M&A deals, rumors and chatter circulating on Wall Street for Thursday, March 9, 2017.
Novo Nordisk CEO Confirms M&A Aspirations, Won't Confirm GBT is Target
The CEO Comments:
Novo Nordisk's (NYSE: NVO) CEO Lars...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Novo Nordisk A/S (NVO):